$100.31
3.03% yesterday
NYSE, Jan 06, 10:04 pm CET
ISIN
IE00BTN1Y115
Symbol
MDT

Medtronic Stock price

$100.31
-0.95 0.94% 1M
+12.64 14.42% 6M
+4.25 4.42% YTD
+20.47 25.64% 1Y
+19.45 24.05% 3Y
-18.55 15.61% 5Y
+24.11 31.64% 10Y
+41.39 70.25% 20Y
NYSE, Closing price Tue, Jan 06 2026
+2.95 3.03%

New AI Insights on Medtronic Insights AI Insights on Medtronic

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$124.8b
Enterprise Value
$145.6b
Net debt
$20.8b
Cash
$8.3b
Shares outstanding
1.3b
Valuation (TTM | estimate)
P/E
26.3 | 17.1
P/S
3.6 | 3.4
EV/Sales
4.2 | 4.0
EV/FCF
28.0
P/B
2.6
Dividends
DPS
$2.80
Yield 1Y | 5Y
2.9% | 2.7%
Growth 1Y | 5Y
1.4% | 5.3%
Payout 1Y | 3Y
77.6% | 90.1%
Increased
25 Years
Financials (TTM | estimate)
Revenue
$34.8b | $36.4b
EBITDA
$8.7b | $10.2b
EBIT
$6.8b | $9.1b
Net Income
$4.8b | $7.3b
Free Cash Flow
$5.2b
Growth (TTM | estimate)
Revenue
5.3% | 8.6%
EBITDA
8.8% | 21.8%
EBIT
7.3% | 39.1%
Net Income
11.1% | 56.7%
Free Cash Flow
-5.3%
Margin (TTM | estimate)
Gross
65.6%
EBITDA
24.9% | 28.0%
EBIT
19.4%
Net
13.7% | 20.1%
Free Cash Flow
15.0%
Financial Health
Equity Ratio
52.4%
Return on Equity
9.7%
ROCE
8.3%
ROIC
7.2%
Debt/Equity
0.6
More
EPS
$3.7
FCF per Share
$4.1
Short interest
1.2%
Employees
95k
Rev per Employee
$350.0k
Show more

Is Medtronic a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,084 stocks worldwide.

Medtronic Stock Analysis

Unlock Scores for Free

Analyst Opinions

39 Analysts have issued a Medtronic forecast:

20x Buy
51%
18x Hold
46%
1x Sell
3%

Analyst Opinions

39 Analysts have issued a Medtronic forecast:

Buy
51%
Hold
46%
Sell
3%

Financial data from Medtronic

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Oct '25
+/-
%
34,758 34,758
5% 5%
100%
- Direct Costs 11,966 11,966
5% 5%
34%
22,792 22,792
6% 6%
66%
- Selling and Administrative Expenses 11,200 11,200
4% 4%
32%
- Research and Development Expense 2,839 2,839
3% 3%
8%
8,652 8,652
9% 9%
25%
- Depreciation and Amortization 1,902 1,902
14% 14%
5%
EBIT (Operating Income) EBIT 6,750 6,750
7% 7%
19%
Net Profit 4,764 4,764
11% 11%
14%

In millions USD.

Don't miss a Thing! We will send you all news about Medtronic directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Medtronic Stock News

Neutral
PRNewsWire
one day ago
GALWAY, Ireland, Jan. 5, 2026 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it will participate in the 44th annual J.P. Morgan healthcare conference on Monday, January 12, 2026.
Positive
The Motley Fool
5 days ago
Visa has a resilient business, a solid competitive edge, and attractive avenues for growth. Medtronic is performing well, and new product launches are providing a potentially long-lasting tailwind.
Positive
Seeking Alpha
6 days ago
The ProShares S&P 500 Dividend Aristocrat ETF (NOBL) underperformed SPY in 2025, gaining 7.2% versus SPY's 18.42%. Despite average underperformance, select Aristocrats like CAH (+74.18%), ALB (+66.90%), and CHRW (+61.22%) delivered strong double-digit returns. Dividend growth for the Aristocrats slowed to 5.52% in 2025, down from 5.78% in 2024, with 68 of 69 raising payouts.
More Medtronic News

Company Profile

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiac and Vascular Group; Minimally Invasive Technologies Group; Restorative Therapies Group; and Diabetes Group. The Cardiac and Vascular Group segment consist Cardiac Rhythm and Heart Failure, Coronary and Structural Heart, and Aortic and Peripheral Vascular divisions. The Minimally Invasive Technologies Group segment comprises Surgical Innovations and Respiratory, Gastrointestinal, and Renal divisions. The Restorative Therapies Group contains Spine, Brain, Specialty Therapies, and Pain Therapies divisions. The Diabetes Group segment focuses in the development, manufacturing, and marketing of products and services for the management of Type I and Type II diabetes. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Head office United States
CEO Geoffrey Martha
Employees 95,000
Founded 2014
Website www.medtronic.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today